Amedisys (NASDAQ:AMED) PT Lowered to $210.00 at Deutsche Bank Aktiengesellschaft

Amedisys (NASDAQ:AMEDGet Rating) had its target price dropped by Deutsche Bank Aktiengesellschaft from $230.00 to $210.00 in a research note issued to investors on Friday, The Fly reports. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential upside of 59.22% from the company’s previous close.

AMED has been the topic of several other reports. SVB Leerink raised their target price on Amedisys from $145.00 to $147.00 and gave the company a “market perform” rating in a report on Friday, February 18th. Raymond James dropped their price objective on Amedisys from $200.00 to $180.00 in a research note on Friday. Truist Financial dropped their price objective on Amedisys from $210.00 to $200.00 and set a “buy” rating on the stock in a research note on Friday, February 25th. Credit Suisse Group dropped their price objective on Amedisys from $200.00 to $195.00 and set an “outperform” rating on the stock in a research note on Friday, February 25th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $200.00 price objective on shares of Amedisys in a research note on Thursday, April 7th. Seven research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $191.06.

NASDAQ AMED opened at $131.89 on Friday. Amedisys has a fifty-two week low of $122.12 and a fifty-two week high of $292.97. The stock’s 50-day moving average is $156.26 and its two-hundred day moving average is $154.20. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.95 and a quick ratio of 0.95. The firm has a market cap of $4.29 billion, a P/E ratio of 20.80, a price-to-earnings-growth ratio of 2.46 and a beta of 0.72.

Amedisys (NASDAQ:AMEDGet Rating) last posted its earnings results on Wednesday, April 27th. The health services provider reported $1.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.12 by $0.11. Amedisys had a return on equity of 21.84% and a net margin of 9.44%. During the same quarter last year, the company earned $1.54 EPS. On average, equities analysts expect that Amedisys will post 5.31 EPS for the current year.

In other Amedisys news, insider David L. Kemmerly sold 2,500 shares of Amedisys stock in a transaction that occurred on Tuesday, March 29th. The stock was sold at an average price of $177.31, for a total transaction of $443,275.00. Following the sale, the insider now directly owns 16,336 shares of the company’s stock, valued at $2,896,536.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.80% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in AMED. Riverbridge Partners LLC boosted its holdings in shares of Amedisys by 57.0% in the 4th quarter. Riverbridge Partners LLC now owns 1,588,750 shares of the health services provider’s stock worth $257,187,000 after acquiring an additional 576,633 shares in the last quarter. Mackenzie Financial Corp raised its position in Amedisys by 39,235.8% in the 4th quarter. Mackenzie Financial Corp now owns 570,369 shares of the health services provider’s stock worth $92,331,000 after purchasing an additional 568,919 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Amedisys in the 4th quarter worth approximately $85,286,000. Capital Research Global Investors raised its position in Amedisys by 2,265.4% in the 3rd quarter. Capital Research Global Investors now owns 406,854 shares of the health services provider’s stock worth $60,662,000 after purchasing an additional 389,654 shares during the last quarter. Finally, Credit Suisse AG raised its position in Amedisys by 233.6% in the 3rd quarter. Credit Suisse AG now owns 463,866 shares of the health services provider’s stock worth $69,162,000 after purchasing an additional 324,806 shares during the last quarter. 92.18% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Company Profile (Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Featured Articles

The Fly logo

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.